세계의 인플루엔자 백신 시장 규모는 2024년에 72억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 128억 달러에 이르고, 2025-2033년까지 6.7%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 시장을 독점하고 있는 것은 북미로, 2024년에는 53.4% 이상 시장 점유율을 차지했습니다. 인플루엔자 백신 시장의 성장을 뒷받침하는 주요 요인으로는 예방접종 프로그램을 지원하는 정부기관에 의한 많은 적극적인 이니셔티브의 개시, 인플루엔자와 계절성 유행 증례 증가, 보다 효과적이고 폭넓은 예방 효과를 가지는 인플루엔자 백신 등이 있습니다.
세계 인플루엔자 백신 시장은 계절성 인플루엔자에 대한 의식이 증가하고 건강 관리 지출이 증가하는 등 여러 요인에 의해 성장하고 있습니다. 또한 인플루엔자 감염으로 인한 합병증을 일으키기 쉬운 노인 인구 증가도 시장을 견인하는 요인 중 하나입니다. 세계 각국의 정부는 백신접종 프로그램에 자원을 투입하고 있습니다. 이것은 시장의 성장에 긍정적으로 기여합니다. COVID-19의 유행은 예방 의학의 이론적 근거를 강화하고 많은 사람들이 치료보다 예방의 중요성을 이해하기 시작했기 때문에 인플루엔자 백신 섭취가 증가했습니다. mRNA 기반 백신과 같은 새로운 백신 개발 방법으로 백신의 안전성과 효율성이 향상되었습니다. 게다가 인플루엔자 균주의 수가 증가하고 매년 예방접종을 받을 의무가 있기 때문에 수요는 끊이지 않습니다. 특히 신흥 국가에서 의료시설 증가는 백신의 사용과 수용을 더욱 증가시킬 것으로 보입니다.
미국은 독감 백신의 주요 지역 시장으로 부상하고 있습니다. 2024년 11월 현재 미국은 2024-25년 시즌에 1억 3,419만 회의 독감 백신을 배포하고 있습니다. 미국의 백신 공급은 주로 민간 제조업체에 의존하고 있으며, 이번 시즌 인플루엔자 백신의 총 복용량은 1억 4,800만 번으로 예측됩니다. 이 공급량 증가는 미국 시장에서 인플루엔자 백신 시장 수요 증가를 반영하고 있으며, 특히 노인과 만성 질환을 가진 사람들과 같은 위험이 높은 사람들 사이에서 계절성 감염의 발생을 예방할 필요성이 높아지고 있습니다. 미국의 인플루엔자 백신 시장은 4가 백신과 mRNA 백신과 같은 백신 기술의 혁신에 힘입어 정부의 백신 접종 프로그램에 지지되어 확대를 계속하고 있습니다. 백신의 가용성과 효율성의 지속적인 개선으로 제조업체는 더 높은 수요 예측에 대응하고 시장은 지속적인 성장을 목표로 하고 있습니다.
계절성 독감 유행과 유행성 증가
계절성 인플루엔자 증가로 입원률이 상승하고 있습니다. 예를 들어, 미국에서는 2022-2023년 인플루엔자 시즌에 3,100만 명의 인플루엔자 환자가 발생했습니다. 게다가 2021-2022년 인플루엔자 시즌 동안 독감으로 인한 사망자 수는 4,977명이었습니다. 이 외에도 미국에서는 인구의 대부분이 예방 접종을 받지 않았습니다. 게다가 2021-2022년까지 18-49세에서는 37%밖에 독감 예방접종을 받지 않았으며, 이는 어린이나 노인에 비해 상당히 낮은 수치였습니다. 따라서 인플루엔자 예방접종의 중요성을 강조하는 의료기관의 주목도가 높아지고 있으며, 시장 성장을 가속하고 있습니다. 예를 들어, 2023년 2월 세계보건기구(WHO)는 2023-2024년의 인플루엔자 시즌을 향해 인플루엔자 백신의 바이러스 구성에 관한 권장 사항을 발표했습니다. 이 발표는 인플루엔자 바이러스 백신의 조성에 관한 4일간의 회의가 끝나면서 설명회에서 진행되었습니다.
인플루엔자 백신 접종에 대한 의식 증가
계절성 인플루엔자의 유행이 확대되고 있는 것이 주로 시장의 성장을 뒷받침하고 있습니다. 예를 들어, 2022년 2월에 발표된 세계 인플루엔자 데이터는 세계에서 추정된 10억 명이 계절성 인플루엔자에 감염되었다고 언급합니다. 이에 따라, 이 10억명 중 매년 약 300만-500만명이 인플루엔자의 중증례에 걸려 있다고 기재되어 있습니다. 또한 WHO가 2022년 12월에 발표한 데이터에 따르면 유럽에서는 인구의 5-15%가 인플루엔자를 앓고 있었습니다. 마찬가지로 2021년 7월에 발표된 Plos One Journal의 논문에서는 인플루엔자의 신규 감염 사례의 약 5-10%, 20-30%가 매년 소아와 성인 사이에서 발생하고 있다고 말하고 있습니다. 인플루엔자 바이러스 증례 증가는 인플루엔자 백신 접종에 대한 개인의 의식을 높여 시장 전체의 성장에 밝은 전망을 가져옵니다. 이 외에도 의료기관은 예방접종의 이점에 관한 정보를 제공하는 캠페인을 실시하고 있어 인플루엔자 백신 수요를 촉진하고 있습니다. 예를 들어, Sanofi가 2022년 6월에 실시한 건강 관리 조사에서는 약사와 의사가 미국 질병 예방 관리 센터(CDC)에 65세 이상의 인플루엔자 치료를 위해 Fluzone high dose quadrivalent와 같은 백신을 제공하도록 권장했다고 보고되었습니다. 모든 연령대의 개인에 대한 지향적 증가는 예측 기간에 걸쳐 독감 백신 시장 점유율을 계속 밀어 올릴 것으로 보입니다.
정부 기관의 지원 증가
세계 정부 기관이 주요 기업과 제휴하여 인플루엔자 백신의 연구 개발을 촉진하고 있습니다. 인플루엔자 백신 시장 통계에 따르면, 2021년 9월 질병 대책 예방 센터(CDC)는 신종 인플루엔자 백신의 선행 개발에 자금을 제공하는 바이오메디컬 선행 연구개발국(BARDA)이 주도하는 광범위한 부처간 파트너십에 참가했습니다. 게다가 정부기관은 라이선스 승인 절차의 합리화 및 고도화를 진행하고 있어, 이것이 인플루엔자 백신 시장 수요 증가에 기여하고 있습니다. 예를 들어, 2022년 7월, 미국 FDA는 GlaxoSmithKline에서 4가 독감 백신 Fluarix의 허가 신청을 승인했습니다. 또한 정부는 인플루엔자 백신 개발에 관한 임상시험과 연구개발비에 지출하고 있습니다. 예를 들어, 2022년 3월 호주 정부 기관은 위험이 높은 개인에 대한 계절성 인플루엔자 백신 접종에 1억 달러 이상을 보냈습니다. 이 외에도 대규모 건강 관리 기업은 백신 측면에서 혁신적인 첨단 요법의 출시에 크게 투자하고 있기 때문에 인플루엔자 백신 시장 전망에도 긍정적인 영향을 미칩니다.
The global influenza vaccine market size was valued at USD 7.2 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 12.8 Billion by 2033, exhibiting a CAGR of 6.7% from 2025-2033. North America currently dominates the market, holding a market share of over 53.4% in 2024. Some of the key factors supporting the influenza vaccine market growth include the launch of many positive initiatives by government bodies to support vaccination programs, increasing cases of influenza and seasonal outbreaks, and more effective and broadly protective influenza vaccines.
The global influenza vaccine market is witnessing growth on account of several factors, factors such as rising awareness regarding the seasonal flu and increasing healthcare spending. The increasing elderly population who are more prone to complications arising from flu infections is also another driving factor. Governments worldwide are channeling resources into vaccination programs. This in turn contributes positively toward the growth of the market. The COVID-19 pandemic reinforced the rationale for preventive medicine, thus increasing the uptake of flu vaccines, as many people began to understand the importance of prevention over treatment. With new ways of developing vaccines such as mRNA-based vaccines, safety, and efficiency of vaccines have improved. Moreover, due to the rising number of influenza strains, and the requirement that individuals be vaccinated every year, there is perpetual demand. The rise of health care facilities particularly in developing countries is likely to increase further the usage and acceptance of vaccines.
The United States has emerged as a key regional market for influenza vaccines. As of November 2024, the US has distributed 134.19 million doses of the flu vaccine for the 2024-25 season. Vaccine supply in the U.S. largely depends on private manufacturers, with projections for a total of 148 million doses of influenza vaccine for the current season. This increasing supply reflects the growing demand within the influenza vaccine market in the U.S. market, driven by the need to prevent seasonal outbreaks, particularly among high-risk populations such as the elderly and those with chronic conditions. The influenza vaccine market in the U.S. continues to expand, bolstered by innovations in vaccine technology, such as quadrivalent and mRNA vaccines, and supported by government vaccination programs. With ongoing improvements in vaccine accessibility and efficacy, manufacturers are responding to higher demand projections, positioning the market for continued growth.
Increasing Seasonal Influenza Outbreaks and Pandemics
The rising cases of seasonal influenza are elevating the hospitalization rates. For example, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. Additionally, in 2021-2022, only 37% of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.
The Rising Awareness Towards Influenza Vaccination
The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.
The Growing Support from Government Bodies
Government agencies around the world are partnering with leading companies to facilitate R&D work in the development of influenza vaccines. According to the statistics of the influenza vaccine market, in September 2021, the Centers for Disease Control and Prevention (CDC) joined a broad interagency partnership led by the Biomedical Advanced Research and Development Authority (BARDA) that funded the advanced development of new influenza vaccines. In addition, government bodies are streamlining and upgrading the procedure of license approvals, which is contributing to the growth in demand in the flu vaccine market. For instance, in July 2022, the U.S. FDA sanctioned the appeal from GlaxoSmithKline for the license Fluarix, which is a quadrivalent flu vaccine. To this effect, the government is spending on clinical trials and R&D work on the development of flu vaccines. For example, during March 2022, Australia's governmental entities spent more than USD 100 Million for seasonal influenza vaccination against individuals under high risk. In addition to this, giant health-care corporations are significantly investing in the release of innovative advanced therapies in terms of vaccines, thus also influencing positively in the case of the influenza vaccine market outlook.
Quadrivalent stands as the largest vaccine type in 2024, holding over 69% of the market. Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.
Egg-based leads the market with around 69% of market share in 2024. Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1) pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Pediatric leads the market with over 72% of market share in 2024. Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.
The injection segment remains widely used, particularly intramuscular injections. This segment is expected to grow rapidly due to advancements in injection technologies, such as the development of microneedle patches that aim to simplify administration and improve patient compliance.
On the other hand, nasal spray influenza vaccines provide a needle-free alternative to traditional injections, delivering the vaccine via the nasal mucosa to stimulate a mucosal immune response. Though less common than injectable vaccines, nasal spray options are increasingly favored by individuals, especially children, who may have a fear of needles. The segment is seeing growth due to ongoing research aimed at improving formulations, expanding eligibility to a broader age range, and refining the delivery technology.
In 2024, North America accounted for the largest market share of over 53%. In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins
United States Influenza Vaccine Market Analysis
In 2024, the Unites States accounts for over 70% of the influenza vaccine market in North America. Strong government initiatives, a strong healthcare system, and an aging population are the main factors propelling the industry. Increasing vaccine uptake is largely dependent on the Centers for Disease Control and Prevention's (CDC) annual vaccination efforts. Between 9 and 45 million influenza cases are estimated to occur in the United States each year, according to the CDC, with related hospitalizations and deaths underscoring the importance of prevention. For vulnerable populations, including the elderly, small children, pregnant women, and people with long-term medical issues, influenza vaccination is strongly advised. Interestingly, more than 16% of Americans are 65 years of age or older, a demographic that has far greater influenza complications and is therefore a prime target for vaccination campaigns.
Additionally, technological developments have fueled market expansion. The effectiveness and coverage of vaccines have increased since the advent of quadrivalent vaccines, which offer protection against four influenza strains. The drawbacks of conventional egg-based vaccinations have been overcome by cell-based and recombinant technologies, which shorten production times and increase scalability during epidemics. Innovations like mRNA-based flu vaccines, which promise increased efficacy and quick adaptation to new strains, are the result of pharmaceutical companies like Sanofi, GlaxoSmithKline, and Moderna investing more in research and development. The industry is further supported by public-private collaborations, such as those made possible by the Biomedical Advanced Research and Development Authority (BARDA). Furthermore, a wider population may now get vaccines because to employer-sponsored immunization programs, pharmacy flu clinics, and growing awareness campaigns. The market for influenza vaccines in the US is expected to expand steadily due to this combination of reasons.
Europe Influenza Vaccine Market Analysis
Adoption of influenza vaccines in Europe is being driven by aging populations, universal healthcare systems, and strict government regulations. Free flu vaccination programs have been put in place in nations including the UK, Germany, and France for vulnerable populations, such as the elderly and children. The demand is being driven by the European Centre for Disease Prevention and Control (ECDC), which places emphasis on reaching a 75% immunization target in high-risk populations. The necessity of vaccination has been further highlighted by the rise in comorbidities such as diabetes and cardiovascular disorders, which exacerbate flu-related consequences. With large expenditures in vaccine production facilities, Europe's emphasis on pandemic preparedness also boosts the industry. Large-scale awareness campaigns and school-based immunization programs that target younger populations boost the industry. The growth of mRNA-based flu vaccines in Europe is another emerging driver, offering improved efficacy and rapid production cycles.
Asia Pacific Influenza Vaccine Market Analysis
Large-scale government vaccination initiatives, growing public awareness, and rising healthcare costs all contribute to the market's growth. Leading nations include China, South Korea, and Japan, with Japan attaining yearly immunization rates of more than 50% among its senior citizens. Due to the great potential for influenza transmission, widespread vaccination campaigns are required in densely populated nations like China and India. To increase vaccine access, especially in remote areas, governments are spending money on distribution networks and cold chain infrastructure. Rapid urbanization in emerging nations increases vulnerability to influenza outbreaks and raises demand for vaccines. Furthermore, partnerships between regional producers and international pharmaceutical firms are stimulating innovation, and current clinical studies for next-generation vaccines-like those based on mRNA and intranasal formulations-are expected to propel further expansion.
Latin America Influenza Vaccine Market Analysis
The growing prevalence of seasonal flu and the government's increased emphasis on public health are driving the influenza vaccination industry in Latin America. Brazil and Mexico are important markets because of their sizable populations and pro-immunization laws. Through national immunization programs, governments frequently give away free vaccines to vulnerable populations, like children and the elderly. According to a report by International Federation on Ageing, Brazil has one of the highest rates of influenza vaccination worldwide among older persons (98.2%) and people with long-term illnesses (86.3%) in 2019. The robust government-led influenza vaccination effort, which depends on both in-person and remote mobilization, is primarily responsible for the target populations' compliance.
Middle East and Africa Influenza Vaccine Market Analysis
Growing government initiatives, foreign aid, and growing awareness of preventative healthcare are the main factors propelling the market. To avoid widespread epidemics, nations like Saudi Arabia and the United Arab Emirates have made flu vaccination a priority, especially for pilgrims traveling for events like the Hajj. Accessibility is increased by the WHO's Global Influenza Strategy, which funds immunization campaigns in low- and middle-income African nations. Uptake of the influenza vaccine is increasing in South Africa, where yearly immunization campaigns target vulnerable populations and healthcare staff. Partnerships with international health groups to improve vaccine distribution and awareness are helping to mitigate issues like the lack of adequate healthcare facilities in some areas.
Key players in the influenza vaccine market are significantly driving the market growth through strategic initiatives. These companies are focusing on enhancing vaccine efficacy with advanced technologies like quadrivalent and mRNA-based vaccines, expanding accessibility through partnerships with governments and healthcare providers, and engaging in extensive research and development. Manufacturers are also responding to rising demand by improving vaccine production capacity, with companies like Moderna and AstraZeneca exploring new formulations and delivery methods, such as microneedle patches, to increase patient compliance. Furthermore, these key players are involved in global vaccine distribution, ensuring greater reach and contributing to the overall market expansion.